Literature DB >> 18406228

Hormonal regulation of osteoclast function.

T J Martin1, N Udagawa.   

Abstract

Hormones and cytokines indirectly control the formation of osteoclasts from hemopoietic precursors by acting upon osteoblastic stromal cells and, in some cases, also upon cells of the immune system. These intermediate cells produce factors that act in a paracrine manner to influence precursor proliferation or differentiation. Successful osteoclast formation in vitro requires contact between stromal and hemopoietic cells, leading to the concept of a membrane-associated stromal cell molecule that specifically programs osteoclast differentiation. Attention has been focused further on this by the recent discovery of a soluble member of the tumor necrosis factor (TNF) receptor family which is both a product of and a ligand for osteoblastic stromal cells. Once they are formed in the presence of osteoblasts, osteoclasts are active, and hormones or cytokines do not promote the activity of mature osteoclasts, but more likely influence their survival. Of the two best known hormonal inhibitors of bone resorption in vivo, calcitonin acts directly upon osteoclasts to inhibit their activity, whereas estrogen acts indirectly, via the regulation of several cytokines.

Entities:  

Year:  1998        PMID: 18406228     DOI: 10.1016/s1043-2760(98)00005-8

Source DB:  PubMed          Journal:  Trends Endocrinol Metab        ISSN: 1043-2760            Impact factor:   12.015


  8 in total

1.  IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis.

Authors:  S Kotake; N Udagawa; N Takahashi; K Matsuzaki; K Itoh; S Ishiyama; S Saito; K Inoue; N Kamatani; M T Gillespie; T J Martin; T Suda
Journal:  J Clin Invest       Date:  1999-05       Impact factor: 14.808

2.  Osteoclast derivation from mouse bone marrow.

Authors:  Ruth Tevlin; Adrian McArdle; Charles K F Chan; John Pluvinage; Graham G Walmsley; Taylor Wearda; Owen Marecic; Michael S Hu; Kevin J Paik; Kshemendra Senarath-Yapa; David A Atashroo; Elizabeth R Zielins; Derrick C Wan; Irving L Weissman; Michael T Longaker
Journal:  J Vis Exp       Date:  2014-11-06       Impact factor: 1.355

3.  Bioinspired polydopamine and polyphenol tannic acid functionalized titanium suppress osteoclast differentiation: a facile and efficient strategy to regulate osteoclast activity at bone-implant interface.

Authors:  Chris Steffi; Zhilong Shi; Chee Hoe Kong; Wilson Wang
Journal:  J R Soc Interface       Date:  2019-03-29       Impact factor: 4.118

4.  Prostaglandin G/H synthase-2 is required for maximal formation of osteoclast-like cells in culture.

Authors:  Y Okada; J A Lorenzo; A M Freeman; M Tomita; S G Morham; L G Raisz; C C Pilbeam
Journal:  J Clin Invest       Date:  2000-03       Impact factor: 14.808

5.  Enhanced osteoclastogenesis by mitochondrial retrograde signaling through transcriptional activation of the cathepsin K gene.

Authors:  Manti Guha; Satish Srinivasan; Alexander Koenigstein; Mone Zaidi; Narayan G Avadhani
Journal:  Ann N Y Acad Sci       Date:  2015-03-18       Impact factor: 5.691

6.  Estrogens suppress RANK ligand-induced osteoclast differentiation via a stromal cell independent mechanism involving c-Jun repression.

Authors:  N K Shevde; A C Bendixen; K M Dienger; J W Pike
Journal:  Proc Natl Acad Sci U S A       Date:  2000-07-05       Impact factor: 11.205

7.  Bortezomib prevents ovariectomy-induced osteoporosis in mice by inhibiting osteoclast differentiation.

Authors:  Sung-Hyun Kim; Myoung Ok Kim; Hyo Jeong Kim; Sanjiv Neupane; Hyung Joon Kim; Ji Hye Lee; Hong-Hee Kim; Jae-Young Kim; Youngkyun Lee
Journal:  J Bone Miner Metab       Date:  2017-10-12       Impact factor: 2.626

Review 8.  Application of specialized pro-resolving mediators in periodontitis and peri-implantitis: a review.

Authors:  Muhanad Ali; Fang Yang; Adelina S Plachokova; John A Jansen; X Frank Walboomers
Journal:  Eur J Oral Sci       Date:  2021-02-09       Impact factor: 2.612

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.